Merck & Co. Seeds Neuroscience Expansion With Caraway Buy
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.